Corvus reports Q2 2026 net loss of $18.0M; cash $215.2M, runway into 2Q28

Corvus Pharmaceuticals, Inc.

Net loss $18.0M in Q2 2026 vs $8.0M in Q2 2025; R&D expenses $16.0M vs $7.9M.
Cash, equivalents and marketable securities $215.2M at June 30, 2026 (incl. $189.4M from Jan 2026 financing) vs $56.8M at Dec 2025; runway into 2Q28.
Soquelitinib Phase 3 PTCL and Phase 2 atopic dermatitis enrollment on track; plans to start hidradenitis suppurativa and asthma trials later 2026.
Invested $5.0M in Angel Pharma equity financing for soquelitinib trials in China.
Angel Pharma to initiate Phase 2 asthma trial early 2027; Corvus to start Phase 1b hidradenitis suppurativa and Phase 2 asthma trials later 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.